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A B S T R A C T
Objective: To determine whether fat mass and obesity-associated gene polymorphisms rs9939609 T>A
and rs8050136 A>C or their haplotypes inﬂuence anthropometric and metabolic variables in recently
postmenopausal women receiving hormone therapy.
Study design: In this randomized crossover study carried out in a university clinic, 86 postmenopausal
women consulting for symptoms of estrogen deﬁciency were genotyped by real-time polymerase chain
reaction for single nucleotide polymorphisms rs9939609 T>A and rs8050136 A>C of the fat mass and
obesity-associated gene. Haplotypes were constructed from the combination of polymorphisms
rs9939609 and rs8050136, and their frequencies were inferred using the PHASE 2.1.1 program.
Participants were clinically evaluated before and after 6 months of hormone therapy to determine body
mass index (current kg/m2) and waist circumference, blood pressure, lipid proﬁle (total cholesterol, HDL
cholesterol and triglycerides) plasma glucose (oral glucose tolerance test), and insulin. Blood samples
were also drawn for ultra sensitive C reactive protein. The lipid accumulation product index was
calculated as (waist [cm] – 58)  triglyceride concentration (mmol/L). Non-normally distributed
parameters were log10 transformed before statistical analysis. Measurements at baseline and at follow-
up were compared with ANOVA for repeated measures. Data were considered signiﬁcant at P < 0.05.
Results: In women with the homozygous polymorphic AA genotype of the single nucleotide
polymorphisms rs9939609 and the wild AA genotype of the single nucleotide polymorphisms
rs8050136, lipid accumulation product index and ultra sensitive C reactive protein were higher before
hormone therapy in comparison with women with other genotypes from the same single nucleotide
polymorphisms group. There was no worsening of any of the anthropometric or metabolic variables, and
lipid accumulation product index improved slightly after hormone therapy in SNP rs9939609 (P = 0.03)
and haplotype AAAA. No changes were observed after hormone therapy in SNP rs8050136.
Conclusions: The presence of fat mass and obesity-associated gene risk variants in healthy early
postmenopausal women does not adversely affect their response to hormone therapy.
 2012 Elsevier Ireland Ltd. 
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In the postmenopausal period, women experience an expo-
nential increase in the risk of cardiovascular disease, the leading
cause of death in this population [1]. During the reproductive
years, endogenous estrogens exert beneﬁcial effects on endothe-
lial function and lipids, and the estrogen deﬁciency that occurs
after the menopause has been related to a worsening in the clinical§ This study was conducted at Hospital de Clı´nicas de Porto Alegre (HCPA), Porto
Alegre, Brazil.
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Open access under the Elsevier OA license.and metabolic proﬁle in this population. Studies have shown an
increase in the incidence of diabetes, hypertension, and dyslipi-
demia, as well as increased risk for the metabolic syndrome, even
after adjustment for confounding variables [2]. Deposition of
abdominal fat is also increased as compared to peripheral fat [3].
Prospective randomized trials have shown that hormone therapy
(HT) is not beneﬁcial for primary or secondary cardiovascular
prevention [4,5]. A recent analysis, however, indicates that HT
may be safe for recently postmenopausal women in whom
atherosclerosis is still not entirely established [6].
Recently, single nucleotide polymorphisms (SNPs) rs9939609 T/
A and rs8050136 A/C of the fat mass and obesity-associated (FTO)
gene have been linked to body mass index (BMI), risk of obesity,
adiposity, metabolic syndrome and high cardiovascular risk in both
men and women. A case–control study from the Women’s Health
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showed an association of polymorphisms rs9939609 and rs8050136
with BMI and waist circumference in white and Hispanic
postmenopausal women, but no association was observed with
obesity-related metabolic traits, including systolic blood pressure,
diastolic blood pressure, plasma fasting insulin, glucose, and ultra
sensitive C reactive protein (us-CRP), a reliable marker of
cardiovascular risk [7]. In turn, we have recently shown an
association of these FTO gene variants with the lipid accumulation
product (LAP) index, which is also a marker of postmenopausal
cardiovascular and metabolic risk [8]. LAP is based on a combination
of two measurements: waist circumference and the fasting
concentration of triglycerides. Studies have shown an association
of LAP with cardiovascular risk factors and metabolic comorbidities
in a healthy population [9,10]. There are, however, no studies in the
literature evaluating whether the presence of FTO gene variants
inﬂuences the effects of HT in postmenopausal women.
Therefore, the aim of the present study was to assess whether
FTO gene polymorphisms rs9939609 T>A and rs8050136 A>C are
associated with changes in anthropometric and metabolic vari-
ables and us-CRP levels in recently postmenopausal women
receiving HT.
2. Materials and methods
2.1. Patients
This randomized crossover study was carried out with women
consulting for climacteric symptoms at the Gynecological Endo-
crinology Unit in a university hospital (Hospital de Clı´nicas de
Porto Alegre) in Brazil. Eighty-six postmenopausal women
fulﬁlling the following inclusion criteria were consecutively
enrolled: last menstrual period between 6 months and 3 years
before the beginning of the study plus follicle-stimulating
hormone levels higher than 35 IU/L; age between 42 and 58
years; no use of any medication known to interfere with hormonal,
glucose, or lipoprotein levels in the past 3 months; no use of
steroidal or nonsteroidal anti-inﬂammatory drugs in the last 15
days. Patients with diabetes, previous hysterectomy, endometrial
thickness >0.5 cm, history of cancer, thromboembolism, or
established cardiovascular disease were excluded [11]. Approval
for this study was obtained from the Institutional Review Board
and the local Ethics Committee, and written informed consent was
obtained from every subject. The study was registered at
clinicaltrials.gov (NCT01432028).
2.2. Study protocol
The sample has been partially described in a previous crossover
randomized study [11] focusing on the effects of low-dose oral HT
and non-oral HT on endothelial function markers and metabolic
variables in early postmenopausal women. Brieﬂy, women were
randomized to receive non-oral HT (3 mg/day intranasal estradiol
daily or 1.5 mg/day transdermal estradiol and 200 mg/day vaginal
micronized progesterone for 14 days/month) or low-dose oral HT
(oral estradiol 1 mg and drospirenone 2 mg/day) for 3 months. Then
the two groups were crossed over without washout for an additional
3 months. In the present study, the correlation between genotype
and us-CRP, anthropometric and metabolic variables was evaluated
before and after 6 months with both forms of HT considered together.
2.3. Anthropometric measurements
Anthropometric measurements included body weight, height,
BMI (current kg/m2) and waist circumference (waist measured at
the midpoint between the lower rib margin and the iliac crest,perpendicularly to the long axis of the body, with the subject
standing balanced on both feet, spread approximately 20 cm apart,
with both arms hanging freely, WC) [12]. Blood pressure was
measured after a 10 min rest. The same calibrated mercury
manometer attached to a 12.5 cm  23 cm inﬂatable cuff was used
in all patients by the same operator. The ﬁfth Korotkoff sound was
adopted to determine diastolic blood pressure [13].
2.4. Laboratory measurements
Blood samples were collected before and after treatment. All
samples were obtained between 08:00 and 10:00 a.m. After a 12-h
overnight fast, blood samples were drawn from an antecubital vein
for determination of lipid proﬁle (total cholesterol, HDL cholesterol
and triglycerides) plasma glucose (oral glucose tolerance test), and
insulin. Blood samples were also drawn for us-CRP. LDL cholesterol
was estimated indirectly with the Friedewald formula [14]. The
LAP index was calculated using the formula [waist (cm) –
58]  triglyceride concentration (mmol/L) [10].
2.5. Biochemical and hormone assays
Total cholesterol, HDL cholesterol and triglycerides were
determined by colorimetric-enzymatic methods (Bayer 1650
Advia System, Deerﬁeld, USA), with intra- and inter-assay
coefﬁcients of variation (CV) <3%. Glucose was determined by
the hexokinase method with intra-assay CV <3.4% and interassay
CV <2.1%. Us-CRP concentrations were measured using a
nephelometric method (Siemens Dade Behring, Deerﬁeld, USA),
with sensitivity of 0.17 mg/L and intra- and inter-assay CV <5%.
Serum insulin levels were determined by electrochemilumines-
cent immunoassays (Roche Diagnostics) with sensitivity of
0.200 mIU/mL, intra-assay CV 2.0% and interassay CV 4.3%.
2.6. Genotyping
In addition to serum samples, whole blood samples were
collected from all women. Genomic DNA was extracted from
peripheral leukocytes following the technique described by Miller
and associates [15]. The DNA samples were diluted to 2 ng/mL and
genotyped for SNP rs9939609 T>A and rs8050136 A>C of the FTO
gene by real-time polymerase chain reaction (7500 Fast Real-Time
polymerase chain reaction Systems, Applied Biosystems, CA, USA),
using the allelic discrimination assay with TaqMan MGB primers
and probes (Applied Biosystems, CA, USA). For a ﬁnal volume of
4 mL per sample, TaqMan Master mix (2.5 mL), TaqMAn assay
(0.250 mL) and H20 (1.250 mL) were added. For a total reaction
volume of 5 mL, 1 mL of DNA was added. Reaction conditions for
the SNP rs9939609 were: 95 8C (10 min) after 50 cycles of
denaturation at 95 8C (15 s) and annealing at 61 8C (1 min).
Reaction conditions for rs8050136 were: 95 8C (10 min) after 40
denaturation cycles at 95 8C (15 s) and annealing at 60 8C (1 min).
Endpoint ﬂuorescent readings were performed by 7500 Fast
System Sequence Detection Software version 1.4.
We calculated Lewontin’s D0 (jD0j) r2 between each pair of
genetic markers for estimating the linkage disequilibrium [16,17].
Haplotypes were constructed from the combination of the two FTO
polymorphisms (rs9939609 and rs8050136), and their frequencies
were inferred using the PHASE 2.1.1 program [18]. The ﬁrst letter of
each haplotype refers to the rs8050136 polymorphism, and the
second to the rs9939609 polymorphism.
2.7. Statistical analysis
Results are expressed as means  SD or medians and inter-
quartile range (25–75%). Analysis of variance for Latin square design
Table 1
Distribution of anthropometric and metabolic variables according the genotype of SNP rs9939609 in postmenopausal women before and 6 months after hormone therapy.
T/T T/A A/A p
Baseline 6 months Baseline 6 months Baseline 6 months
Waist circumference (cm) 84.7  8.2 84.0  8.1 83.3  7.1 81.7  7.3 84.7  5.0 84.0  3.9 0.42
Body mass index (kg/m2) 26.6  2.8 26.4  2.8 25.9  3.4 25.9  3.6 25.8  2.6 25.5  2.2 0.51
Systolic blood pressure (mmHg) 119  13 117  13 117  14 114  14 122  12 114  14 0.41
BP (mmHg) 77  6 76  7 74  8 74  9 78  3 75  7 0.54
Fasting glucose (mg/dL) 93.1  9.2 92.0  7.2 88.7  7.5 89.9  7.85 100.0  18.7 101.3  13.9 0.37
Glucose at 120 min (mg/dL) 102.6  22.4 102.8  29.6 100.5  27.7 110.9  36.2 121.3  36.8 138.3  43.9 0.12
Fasting insulin (mUI/mL) 7.9 (5.8–10.4) 7.2 (5.5–11.8) 5.7 (4.2–8.7) 6.5 (4.7–9.3) 7.0 (6.2–9.4) 6.1 (4.8–7.4) 0.59
Serum cholesterol (mg/dL) 216.0  33.6 193.7  39.4 212.3  27.6 196.9  27.3 230.5  20.0 216.3  47.1 0.74
HDL-c (mg/dL) 63.8  18.6 57.2  16.8 62.5  13.3 58.9  12.0 63.5  10.7 61.2  14.9 0.28
LDL-c (mg/dL) 129.3  31.9 119.6  28.4 125.9  24.9 112.2  26.3 136.2  21.5 129.6  35.3 0.71
Serum triglycerides (mg/dL) 108.8  52.3 115.3  59.4 116.9  51.0 127.6  62.4 153.8  52.3 122.1  44.9 0.05
C reactive protein (mg/L) 1.2 (0.6–2.9) 1.4 (0.4–2.5) 1.5 (0.7–2.8) 2.1 (0.8–3.3) 2.1 (1.1–4.1) 1.2 (0.6–1.8) 0.19
Lipid accumulation product 28.8 (17.4–42.6) 29.5 (18.0–46.9) 29.3 (18.4–43.8) 26.7 (15.4–52.7) 49.9 (31.0–53.6) 32.9 (23.0–46.4) 0.03
Data are mean  SD values median and interquartile range (25–75%) (ANOVA for repeated measures); p = interaction of HT and genotype, i.e. comparisons before and after 6 months
of hormone treatment in each group and between genotype groups.
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and carryover effects. No carryover was observed for any variable.
Non-normally distributed parameters were log10 transformed to
approximate a normal distribution curve before statistical analysis.
Differences between measurements at baseline and at follow-up
were tested with ANOVA for repeated measures. Data were
considered signiﬁcant at P < 0.05.
All analyses were performed using the Statistical Package for
the Social Sciences 18 (SPSS, Chicago, IL, USA).
3. Results
The mean age of participants was 51  3 years. The mean time
since menopause was 22  10 months. Patients were mostly
Caucasian (90.6%), with the remaining participants having mixed
(African and European) descent. While BMI and glucose remained
unchanged after HT, waist circumference, systolic blood pressure,
total cholesterol, HDL-c and LDL-c were reduced after 6 months in the
overall sample (P < 0.05).
Eighty-six patients were genotyped. The frequency of the SNP
rs9939609 was 44.2% for the TT genotype, 40.7% for the TA
genotype, and 10.5% for the AA genotype. The frequency of the SNP
rs8050136 was 13.6% for the AA genotype, 35.8% for the AC
genotype, and 50.6% for the CC genotype. These genotype
frequencies are in agreement with Hardy–Weinberg equilibrium
for both polymorphisms. The rs9939609 polymorphism was in
almost complete linkage disequilibrium with the rs8050136
polymorphism (jD0j = 0953; r2 = 0.876). Five haplotypes were
inferred in this sample (Ht1: CTCT, Ht2: CTCA, Ht3: CTAA, Ht4:
ATAA, Ht5: AAAA). Haplotype frequencies were 46.4% for Ht1,
42.7% for Ht2/Ht3/Ht4, and 10.9% for Ht5.
Table 1 shows the distribution of anthropometric and metabolic
variables according to the genotypes of the SNP rs9939609 in
postmenopausal women before and after HT. Most of the studied
variables remained unchanged after HT, with the exception of LAP,
which were lowered after HT in women with the AA genotype
(P = 0.03).
Table 2 presents the distribution of anthropometric and
metabolic variables according to the genotypes of the SNP
rs8050136 in postmenopausal women before and after HT. No
changes were found among genotypes in the studied variables.
Table 3 shows the distribution of anthropometric and
metabolic variables according to haplotypes. Most of the studied
variables remained unchanged after HT, with the exception of
LAP, which decreased slightly after HT in women presenting
haplotype Ht5.4. Comments
In the present study, FTO gene polymorphisms were not
associated with adverse changes in metabolic variables or us-CRP
levels in response to HT in postmenopausal women. It is important
to note, however, that because of our selection criteria, only women
in the ﬁrst 3 years of the menopause, without clinical evidence of
disease, were included in the study. This may have prevented us
from identifying an association between the investigated SNPs and
altered metabolic variables such as total cholesterol, LDL-c and HDL-
c, which reﬂect a pathologic phenotype.
To the best of our knowledge, this is the ﬁrst study assessing the
relationship between FTO gene polymorphisms and HT. In general,
studies focusing speciﬁcally on the effect of HT in early
postmenopausal women report favorable outcomes. For example,
the Coronary Artery Calcium Study (WHI-CACS) [19], which
included women with age between 50 and 59 years, reported
that beginning HT soon after the menopause contributes to a
reduction in coronary artery calciﬁcation and in the prevalence of
subclinical coronary disease. A reanalysis of WHI data [20] showed
that women starting HT near the menopause also present a
reduction in the risk of developing cardiovascular disease. In
addition, one meta-analysis of randomized clinical trials compar-
ing the results of coronary heart disease after menopausal HT in
young versus older women demonstrated a cardiovascular beneﬁt
of early HT initiation [21].
Our group has also observed that treatment did not affect
variables related to cardiovascular risk in a population of healthy,
early postmenopausal women in a study comparing low-dose oral
HT and nonoral HT [11]. Similarly, in the present study, no changes
were found after HT in the anthropometric and metabolic proﬁle of
postmenopausal women. These observations are supported by
evidence suggesting that HT does not have adverse effects on BMI
[22], blood pressure [23] and vascular function [24].
We observed a strong linkage disequilibrium, consistent with
the ﬁndings of previous studies [25,26], between the two
polymorphisms of the FTO gene. However, even though higher
LAP values were recorded before treatment in women carrying
genotype AA in either SNP or in the Ht 5 haplotype, which contains
both A alleles of the two SNPs, no deleterious LAP changes
occurred after treatment. Concerning the LAP index, results from
the Ludwigshafen risk and cardiovascular health study (LURIC),
which included postmenopausal women at high cardiovascular
risk, have shown a positive association between high LAP and
heart failure mortality in normal weight women [27]. Another
study showed an independent association of LAP levels with
Table 2
Distribution of anthropometric and metabolic variables according to the genotype of SNP rs8050136 in postmenopausal women before and 6 months after hormone therapy.
A/A A/C C/C p
Baseline 6 months Baseline 6 months Baseline 6 months
n (%) 11 (13.6) 11 (13.6) 29 (35.8) 29 (35.8) 41 (50.6) 41 (50.6)
Waist circumference (cm) 82.8  6.2 81.9  5.8 83.6  7.2 82.0  7.5 84.7  7.9 84.0  7.8 0.54
Body mass index (kg/m2) 24.6  3.5 24.4  3.2 26.1  3.2 26.06  3.3 26.7  2.8 26.5  2.86 0.81
Systolic blood pressure (mmHg) 122  12 114  13 116  14 113  15 119  12 117  13 0.48
Diastolic blood pressure (mmHg) 77  4 76  6 74  8 74  9 76  6 76  7 0.95
Fasting Glucose (mg/dL) 97.0  18.2 99.2  13.4 88.4  7.4 89.5  8.1 93.0  8.9 91  7.1 0.23
Glucose at 120 min (mg/dL) 118.2  33.8 134.7  40.2 100.2  30.5 111.8  39.0 102.1  21.6 101.8  28.7 0.07
Fasting insulin (mUI/mL) 7.0 (5.4–9.0) 6.1 (4.7–7.2) 5.7 (4.2–9.1) 6.4 (4.4–9.5) 7.9 (5.8–10.2) 7.2 (5.4–10.3) 0.61
Serum cholesterol (mg/dL) 227.3  19.8 212.0  43.2 211.5  29.8 195.6  29.2 215.6  32.3 195.0  38.4 0.87
HDL-c (mg/dL) 60.4  12.1 58.5  14.8 63.9  13.5 59.7  12.3 64.0  17.9 57.7  16.3 0.35
LDL-c (mg/dL) 136.1  19.9 126.4  32.7 123.8  26.4 109.6  27.8 129.1  30.5 120.6  27.7 0.69
Serum triglycerides (mg/dL) 153.4  47.8 131.1  50.8 116.0  53.1 129.5  63.6 107.2  51.1 111.9  58.2 0.10
C reactive protein (mg/L) 2.1 (1.4–3.3) 1.2 (0.6–1.9) 1.2 (0.6–2.5) 2.1 (0.8–3.4) 1.3 (06–2.9) 1.4 (0.5–2.6) 0.07
Lipid accumulation product 40.9 (26.4–53.6) 32.9 (22.6–43.5) 30.6 (18.2–46.8) 32.7 (15.2–53.1) 27.7 (18.1–42.6) 27.6 (17.9–46.6) 0.10
Data are mean  SD values median and interquartile range (25–75%) (ANOVA for repeated measures); p = interaction of HT and genotype, i.e. comparisons before and after 6 months
of hormone treatment in each group and between genotype groups.
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but not men [28]. This is also in agreement with previous studies
by our group that showed a relationship between LAP and
cardiovascular risk factors [29] as well as with the AA genotypes of
both FTO gene polymorphisms [8].
The mechanism of action of the FTO variant on risk of
metabolic traits and markers of cardiovascular risk remains
uncertain. Recent studies suggest that FTO is a member of the
non-heme superfamily, which encodes 2-oxoglutarate (2-OG)-
dependent dioxygenases [30]. Members of this superfamily are
involved in various cellular processes, including DNA repair,
fatty acid metabolism and post-translational modiﬁcations. The
SNPs rs9939609 and rs8050136 are not likely a causal variant;
SNPs in the ﬁrst intron of the FTO gene are in linkage
disequilibrium with each other and there is not one SNP which
can be treated as tagSNP across all ethnicities [31]. It is unclear
whether these variations inﬂuence FTO expression or splicing or
act as regulatory elements.
Concerning ethnicity, one meta-analysis of studies regarding
the FTO gene and SNPs rs9939609 and rs8050136 provided
signiﬁcant evidence of a modest increase in the risk of obesity in
Caucasian and Asian samples [31]. Another meta-analysis includ-
ing only Asians showed the same polymorphisms associated with
obesity risk in these populations [32]. Nevertheless, ethnic-speciﬁc
associations were not observed between FTO and metabolicTable 3
Distribution of anthropometric and metabolic variables according to the haplotypes of fat
months after hormone therapy.
Ht 1 Ht 2–4
Baseline 6 months Baselin
Waist circumference (cm) 84.7  8.2 84.0  8.1 83.3 
Body mass index (kg/m2) 26.6  2.8 26.4  2.8 25.9 
Systolic blood pressure (mmHg) 119.5  13.0 117.6  13.8 117.0 
Diastolic blood pressure (mmHg) 77  6 76  7 74  8
Fasting glucose (mg/dL) 93.1  9.2 92.0  7.2 88.7 
Glucose at 120 min (mg/dL) 102.6  22.4 102.8  29.6 100.5 
Serum cholesterol (mg/dL) 216  33 193  39 212  2
HDL-c (mg/dL) 63  18 57  16 62  1
LDL-c (mg/dL) 129  31 119  28 125  2
Serum triglycerides (mg/dL) 108  52 115  59 116  5
C reactive protein (mg/L) 1.5 (0.5–2.8) 1.4 (0.4–2.6) 1.7 (
Lipid accumulation product index 28.8 (17.4–42.6) 29.5 (18.0–46.9) 29.3 (
Data are mean  SD values median and interquartile range (25–75%) (ANOVA for repeate
months of hormone treatment in each group and between haplotype groups.variables in a case–control study with postmenopausal women
[7]. Interestingly, a recent meta-analysis has shown that partici-
pants having the FTO risk allele in SNP rs9939609 may have the
odds ratio for obesity attenuated by 27% if they are physically
active [33], suggesting a possible inﬂuence of lifestyle on
phenotype/genotype interactions.
Other FTO gene polymorphisms have been associated with
increased insulin, glucose, cholesterol and triglyceride levels, as
well as with lower HDL-cholesterol levels in several populations
[34,35]. Similarly, a previous study carried out by our group
including most of the participants in the present study found that
the SNP rs9939609 was related to abnormal glucose levels, but not
to other metabolic variables [8]. Further, after adjustment for BMI,
other investigators did not observe an association with insulin,
HOMA-b, glucose and HDL-c [32,36].
In the present study, addressing the impact of FTO gene
polymorphisms on the response to HT, we found no deleterious
inﬂuence of homozygous wild genotype (AA) in the SNP rs8050136
on us-CRP levels after HT in recent postmenopausal women.
Conversely, other studies have associated FTO gene polymor-
phisms with increased levels of CRP and higher cardiovascular risk
in white European [37], and postmenopausal women [8], while
others did not observe this association. Nevertheless, no previous
study has speciﬁcally addressed the inﬂuence of polymorphisms
on the response to HT. mass and obesity-associated gene variants in postmenopausal women before and 6
 Ht 5 p
e 6 months Baseline 6 months
 7.1 81.7  7.3 84.7  5.0 84.0  3.9 0.42
 3.4 25.9  3.6 25.8  2.6 25.5  2.2 0.51
 14.1 114.6  14.1 122.8  114.8 114.8  14.9 0.41
 74  9 78  3 75  7 0.54
 7.5 89.9  7.8 100.0  18.7 101.3  13.9 0.37
 27.7 110.9  36.2 121.3  36.8 138.3  43.9 0.12
7 196  27 230  20 216  47 0.74
3 58  12 63  10 61  14 0.28
4 112  26 136  21 129  35 0.71
1 127  62 153  52 122  44 0.05
0.6–3.3) 2.1 (0.8–3.3) 2.6 (1.0–4.6) 1.2 (0.6–1.8) 0.19
18.4–43.8) 26.7 (15.4–52.7) 49.9 (31.0–53.6) 32.9 (23.0–46.4) 0.03
d measures); p = interaction of HT and haplotype, i.e. comparisons before and after 6
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The presence of fat mass and obesity-associated gene risk
variants in healthy early postmenopausal women does not
adversely affect their response of to hormone therapy.
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